| [1] |
Hart PA, Conwell DL. Chronic Pancreatitis: Managing a Difficult Disease[J]. Am J Gastroenterol, 2020, 115(1): 49-55.
|
| [2] |
An J, Jiang T, Qi L, et al. Acinar cells and the development of pancreatic fibrosis[J]. Cytokine Growth Factor Rev, 2023, 71-72: 40-53.
|
| [3] |
Hu F, Lou N, Jiao J, et al. Macrophages in pancreatitis: Mechanisms and therapeutic potentia[J]l. Biomed Pharmacother, 2020, 131: 110693.
|
| [4] |
Xiao AY, Tan ML, Wu LM, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies[J]. Lancet Gastroenterol Hepatol, 2016, 1(1): 45-55.
|
| [5] |
Barry K, Chronic Pancreatitis: Diagnosis and Treatment[J]. Am Fam Physician, 2018, 97(6): 385-393.
|
| [6] |
Li B Q, Liu X Y, Mao T, et al. The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis[J]. Front Oncol, 2022, 12: 1050274.
|
| [7] |
Cárdenas-Jaén K, Vaillo-Rocamora A, Gracia Á, et al. Simvastatin in the Prevention of Recurrent Pancreatitis: Design and Rationale of a Multicenter Triple-Blind Randomized Controlled Trial, the SIMBA Trial[J]. Front Med(Lausanne), 2020, 7: 494.
|
| [8] |
Apte M, Pirola R, Wilson J, The fibrosis of chronic pancreatitis: new insights into the role of pancreatic stellate cells[J]. Antioxid Redox Signal, 2011, 15(10): 2711-22.
|
| [9] |
Bynigeri R R, Jakkampudi A, Jangala R, et al. Pancreatic stellate cell: Pandora's box for pancreatic disease biology[J]. World J Gastroenterol, 2017, 23(3): 382-405.
|
| [10] |
Cannon A, Thompson CM, Bhatia R, et al. Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinoma[J]. J Gastroenterol, 2021, 56(8): 689-703.
|
| [11] |
Jin G, Hong W, Guo Y, et al. Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer[J]. J Cancer, 2020, 11(6): 1505-1515.
|
| [12] |
Radoslavova S, Folcher A, Lefebvre T, et al. Orai1 Channel Regulates Human-Activated Pancreatic Stellate Cell Proliferation and TGF(β1) Secretion through the AKT Signaling Pathway[J]. Cancers(Basel), 2021, 13(10): 2395.
|
| [13] |
Wu N, Xu XF, Xin JQ, et al. The effects of nuclear factor-kappa B in pancreatic stellate cells on inflammation and fibrosis of chronic pancreatitis[J]. J Cell Mol Med, 2021, 25(4): 2213-2227.
|
| [14] |
Apte MV, Haber PS, Applegate TL, et al. Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture[J]. Gut, 1998, 43(1): 128-33.
|
| [15] |
Schneider E, Schmid-Kotsas A, Zhao J, et al. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells[J]. Am J Physiol Cell Physiol, 2001, 281(2): C532-543.
|
| [16] |
Bachem MG, Schneider E, Gross H, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans[J]. Gastroenterology, 1998, 115(2): 421-32.
|
| [17] |
Mews P, Phillips P, Fahmy R, et al. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis[J]. Gut, 2002, 50(4): 535-41.
|
| [18] |
Luttenberger T, Schmid-Kotsas A, Menke A, et al. Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: implications in pathogenesis of pancreas fibrosis[J]. Lab Invest, 2000, 80(1): 47-55.
|
| [19] |
Li C X, Cui L H, Zhuo Y Z, et al. Inhibiting autophagy promotes collagen degradation by regulating matrix metalloproteinases in pancreatic stellate cells[J]. Life Sci, 2018, 208: 276-283.
|
| [20] |
Shek F W, Benyon R C, Walker F M, et al. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis[J]. Am J Pathol, 2002, 160(5): 1787-98.
|
| [21] |
Ren Y, Zhang J, Wang M, et al. Identification of irisin as a therapeutic agent that inhibits oxidative stress and fibrosis in a murine model of chronic pancreatitis[J]. Biomed Pharmacother, 2020, 126: 110101.
|
| [22] |
Xia D, Halder B, Godoy C, et al. NADPH oxidase 1 mediates caerulein-induced pancreatic fibrosis in chronic pancreatitis[J]. Free Radic Biol Med, 2020, 147: 139-149.
|
| [23] |
Yan B, Cheng L, Jiang Z, et al. Resveratrol Inhibits ROS-Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR-21[J]. Oxid Med Cell Longev, 2018, 2018: 1346958.
|
| [24] |
Ji B, Gaiser S, Chen X, et al. Intracellular trypsin induces pancreatic acinar cell death but not NF-kappaB activation[J]. J Biol Chem, 2009, 284(26): 17488-98.
|
| [25] |
Pandol SJ, Gorelick FS, Lugea A, Environmental and genetic stressors and the unfolded protein response in exocrine pancreatic function - a hypothesis[J]. Front Physiol, 2011, 2: 8.
|
| [26] |
Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response[J]. Nat Rev Mol Cell Biol, 2020, 21(8): 421-438.
|
| [27] |
Xia L, Xu Z, Zhou X, et al. Impaired autophagy increases susceptibility to endotoxin-induced chronic pancreatitis[J]. Cell Death Dis, 2020, 11(10): 889.
|
| [28] |
Diakopoulos K N, Lesina M, Wörmann S, et al. Impaired autophagy induces chronic atrophic pancreatitis in mice via sex- and nutrition-dependent processes[J]. Gastroenterology, 2015, 148(3): 626-638. e17.
|
| [29] |
Wooten M W, Geetha T, Seibenhener M L, et al. The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination[J]. J Biol Chem, 2005, 280(42): 35625-35629.
|
| [30] |
Chen H, Tan P, Qian B, et al. Hic-5 deficiency protects cerulein-induced chronic pancreatitis via down-regulation of the NF-κB(p65)/IL-6 signalling pathway[J]. J Cell Mol Med, 2020, 24(2): 1488-1503.
|
| [31] |
Liu J, Gao M, Nipper M, et al. Activation of the intrinsic fibroinflammatory program in adult pancreatic acinar cells triggered by Hippo signaling disruption[J]. PLoS Biol, 2019, 17(9): e3000418.
|
| [32] |
Roh JS, Sohn DH. Damage-Associated Molecular Patterns in Inflammatory Diseases[J]. Immune Netw, 2018, 18(4): e27.
|
| [33] |
Kang R, Lotze MT, Zeh HJ, et al. Cell death and DAMPs in acute pancreatitis[J]. Mol Med, 2014, 20(1): 466-77.
|
| [34] |
Yang W J, Cao R C, Xiao W, et al. Acinar ATP8b1/LPC pathway promotes macrophage efferocytosis and clearance of inflammation during chronic pancreatitis development[J]. Cell Death Dis, 2022, 13(10): 893.
|
| [35] |
Yao Y, Xu X H, Jin L, Macrophage Polarization in Physiological and Pathological Pregnancy[J]. Front Immunol, 2019, 10: 792.
|
| [36] |
Jancsó Z, Sahin-Tóth M, Chronic progression of cerulein-induced acute pancreatitis in trypsinogen mutant mice[J]. Pancreatology, 2022, 22(2): 248-257.
|
| [37] |
Peng C, Tu G, Yu L, et al. Murine Chronic Pancreatitis Model Induced by Partial Ligation of the Pancreatic Duct Encapsulates the Profile of Macrophage in Human Chronic Pancreatitis[J]. Front Immunol, 2022, 13: 840887.
|
| [38] |
Xue J, Sharma V, Hsieh MH, et al. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis[J]. Nat Commun, 2015, 6: 7158.
|
| [39] |
Habtezion A, Inflammation in acute and chronic pancreatitis[J]. Curr Opin Gastroenterol, 2015, 31(5): 395-399.
|
| [40] |
Pan Z, Van den Bossche JL, Rodriguez-Aznar E, et al. Pancreatic acinar cell fate relies on system x(C)(-) to prevent ferroptosis during stress[J]. Cell Death Dis, 2023, 14(8): 536.
|
| [41] |
Zheng M, Li H, Gao Y, et al. Vitamin D(3) analogue calcipotriol inhibits the profibrotic effects of transforming growth factor- β1 on pancreatic stellate cells[J]. Eur J Pharmacol, 2023, 957: 176000.
|
| [42] |
Qu F, Geng R, Liu Y, et al. Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment[J]. Theranostics, 2022, 12(7): 3372-3406.
|
| [43] |
Chen D, Lei C, Liu W, et al. Reduction-responsive nucleic acid nanocarrier-mediated miR-22 inhibition of PI3K/AKT pathway for the treatment of patient-derived tumor xenograft osteosarcoma[J]. Bioact Mater, 2023, 28: 376-385.
|
| [44] |
Mo L, Liang D, Qin R, et al. Three-Dimensional CHA-HCR System Using DNA Nanospheres for Sensitive and Rapid Imaging of miRNA in Live Cells and Tissues[J]. Anal Chem, 2023, 95(31): 11777-11784.
|
| [45] |
Zhou Y, Yang M, Yan X, et al. Oral Nanotherapeutics of Andrographolide/Carbon Monoxide Donor for Synergistically Anti-inflammatory and Pro-resolving Treatment of Ulcerative Colitis[J]. ACS Appl Mater Interfaces, 2023, 15(30): 36061-36075.
|
| [46] |
Huang J, Huang H, Wang Y, et al. Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation[J]. Biomaterials, 2023, 299: 122134.
|
| [47] |
Mu W, Chu Q, Liu Y, et al. A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy[J]. Nanomicro Lett, 2020, 12(1): 142.
|
| [48] |
Wang F, Li C, Cheng J, et al. Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents[J]. Int J Environ Res Public Health, 2016, 13(12): 1182.
|
| [49] |
Khurana A, Anchi P, Allawadhi P, et al. Superoxide dismutase mimetic nanoceria restrains cerulein induced acute pancreatitis[J]. Nanomedicine(Lond), 2019, 14(14): 1805-1825.
|
| [50] |
Khurana A, Saifi MA, Godugu C, Yttrium Oxide Nanoparticles Attenuate L-Arginine Induced Chronic Pancreatitis[J]. Biol Trace Elem Res, 2023, 201(7): 3404-3417.
|
| [51] |
Khurana A, Saifi MA, Godugu C, Nanoceria Ameliorates Fibrosis, Inflammation, and Cellular Stress in Experimental Chronic Pancreatitis[J]. ACS Biomater Sci Eng, 2023, 9(2): 1030-1042.
|
| [52] |
de Oliveira MA, Araújo RS, Mosqueira VCF. PEGylated and functionalized polylactide-based nanocapsules: An overview[J]. Int J Pharm, 2023, 636: 122760.
|
| [53] |
Wang F, Deng Y, Yu L, et al. A Macrophage Membrane-Polymer Hybrid Biomimetic Nanoplatform for Therapeutic Delivery of Somatostatin Peptide to Chronic Pancreatitis[J]. Pharmaceutics, 2022, 14(11): 2341.
|
| [54] |
Feng WM, Guo HH, Xue T, et al. Anti-inflammation and anti-fibrosis with PEGylated, apigenin loaded PLGA nanoparticles in chronic pancreatitis disease[J]. Rsc Adv, 2015, 5(102): 83628-83635.
|
| [55] |
Wassmann S, Laufs U, Bäumer A T, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[J]. Hypertension, 2001, 37(6): 1450-1457.
|
| [56] |
Weitz-Schmidt G. Statins as anti-inflammatory agents[J]. Trends Pharmacol Sci, 2002, 23(10): 482-6.
|
| [57] |
Bang UC, Watanabe T, Bendtsen F, The relationship between the use of statins and mortality, severity, and pancreatic cancer in Danish patients with chronic pancreatitis[J]. Eur J Gastroenterol Hepatol, 2018, 30(3): 346-351.
|
| [58] |
Mansouri A, Reiner Ž, Ruscica M, et al. Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases[J]. J Clin Med, 2022, 11(5): 1313.
|
| [59] |
Kojayan GG, Alizadeh RF, Li S, et al. Reducing Pancreatic Fibrosis Using Antioxidant Therapy Targeting Nrf2 Antioxidant Pathway: A Possible Treatment for Chronic Pancreatitis[J]. Pancreas, 2019, 48(10): 1259-1262.
|
| [60] |
Wei L, Yamamoto M, Harada M, et al. Treatment with pravastatin attenuates progression of chronic pancreatitis in rat[J]. Lab Invest, 2011, 91(6): 872-884.
|
| [61] |
Schwalfenberg GK. N-Acetylcysteine: A Review of Clinical Usefulness(an Old Drug with New Tricks)[J]. J Nutr Metab, 2021, 2021: 9949453.
|
| [62] |
Zhang J, Bai J, Zhou Q, et al. Glutathione prevents high glucose-induced pancreatic fibrosis by suppressing pancreatic stellate cell activation via the ROS/TGFβ/SMAD pathway[J]. Cell Death Dis, 2022, 13(5): 440.
|
| [63] |
Minati MA, Libert M, Dahou H, et al. N-Acetylcysteine Reduces the Pro-Oxidant and Inflammatory Responses during Pancreatitis and Pancreas Tumorigenesis[J]. Antioxidants(Basel), 2021, 10(7): 1107.
|
| [64] |
Asaumi H, Watanabe S, Taguchi M, et al. Externally applied pressure activates pancreatic stellate cells through the generation of intracellular reactive oxygen species[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 293(5): G972-978.
|
| [65] |
Raghu G, Berk M, Campochiaro PA, et al. The Multifaceted Therapeutic Role of N-Acetylcysteine(NAC) in Disorders Characterized by Oxidative Stress[J]. Curr Neuropharmacol, 2021, 19(8): 1202-1224.
|
| [66] |
Wei Q, Kong N, Liu X, et al. Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro[J]. J Transl Med, 2021, 19(1): 157.
|
| [67] |
Tang Q, Xing C, Li M, et al. Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways[J]. Ecotoxicol Environ Saf, 2022. 244: 114066.
|
| [68] |
Al-Bayati MA, Xie Y, Mohr FC, et al. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats[J]. Biochem Pharmacol, 2002. 64(3): 517-525.
|
| [69] |
Palathingal Bava E, George J, Iyer S, et al. Pirfenidone ameliorates chronic pancreatitis in mouse models through immune and cytokine modulation[J]. Pancreatology, 2022, 22(5): 553-563.
|
| [70] |
El-Kashef DH, Shaaban AA, El-Agamy DS, Protective role of pirfenidone against experimentally-induced pancreatitis[J]. Pharmacol Rep, 2019, 71(5): 774-781.
|
| [71] |
Weissman IL, Anderson DJ, Gage F, Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations [J]. Annu Rev Cell Dev Biol, 2001, 17: 387-403.
|
| [72] |
Burr A, Parekkadan B. Kinetics of MSC-based enzyme therapy for immunoregulation[J]. J Transl Med, 2019. 17(1): 263.
|
| [73] |
Yi T, Song S U, Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications[J]. Arch Pharm Res, 2012. 35(2): 213-221.
|
| [74] |
Zhou CH, Li ML, Qin AL, et al. Reduction of fibrosis in dibutyltin dichloride-induced chronic pancreatitis using rat umbilical mesenchymal stem cells from Wharton's jelly[J]. Pancreas, 2013, 42(8): 1291-1302.
|
| [75] |
Taha HS, Moustafa EM, Moawed FS, et al. Curative role of mesenchymal stromal cells in chronic pancreatitis: Modulation of MAPK and TGF-β1/SMAD factors[J]. Int J Immunopathol Pharmacol, 2021, 35: 20587384211054036.
|
| [76] |
Xu X, Yu H, Sun L, et al. Adipose-derived mesenchymal stem cells ameliorate dibutyltin dichloride-induced chronic pancreatitis by inhibiting the PI3K/AKT/mTOR signaling pathway[J]. Mol Med Rep, 2020, 21(4): 1833-1840.
|
| [77] |
Kong L, Xu X, Zhang H, et al. Human umbilical cord-derived mesenchymal stem cells improve chronic pancreatitis in rats via the AKT-mTOR-S6K1 signaling pathway[J]. Bioengineered, 2021, 12(1): 1986-1996.
|
| [78] |
Sun Z, Gou W, Kim DS, et al. Adipose Stem Cell Therapy Mitigates Chronic Pancreatitis via Differentiation into Acinar-like Cells in Mice[J]. Mol Ther, 2017, 25(11): 2490-2501.
|
| [79] |
Kawakubo K, Ohnishi S, Fujita H, et al. Effect of Fetal Membrane-Derived Mesenchymal Stem Cell Transplantation in Rats With Acute and Chronic Pancreatitis[J]. Pancreas, 2016, 45(5): 707-713.
|
| [80] |
Zhang G, Zhao X, Cai J, et al. XCHT alleviates the pancreatic fibrosis via VDR/NLRP3 signaling pathway in a mouse model of CP[J]. J Ethnopharmacol, 2023, 300: 115689.
|
| [81] |
Duan LF, Xu XF, Zhu LJ, et al. Dachaihu decoction ameliorates pancreatic fibrosis by inhibiting macrophage infiltration in chronic pancreatitis[J]. World J Gastroenterol, 2017, 23(40): 7242-7252.
|
| [82] |
Liang X, Han M, Zhang X, et al. Dahuang Danshen Decoction Inhibits Pancreatic Fibrosis by Regulating Oxidative Stress and Endoplasmic Reticulum Stress[J]. Evid Based Complement Alternat Med, 2021, 2021: 6629729.
|
| [83] |
Liu C, Li S, Zhang Q, et al. Emerging Role of Chinese Herbal Medicines in the Treatment of Pancreatic Fibrosis[J]. Am J Chin Med, 2019, 47(4): 709-726.
|
| [84] |
Choi JW, Shin JY, Zhou Z, et al. Stem bark of Fraxinus rhynchophylla ameliorates the severity of pancreatic fibrosis by regulating the TGF-β/Smad signaling pathway[J]. J Investig Med, 2022, 70(5): 1285-1292.
|
| [85] |
Bansod S, Doijad N, Godugu C. Berberine attenuates severity of chronic pancreatitis and fibrosis via AMPK-mediated inhibition of TGF-β1/Smad signaling and M2 polarization[J]. Toxicol Appl Pharmacol, 2020, 403: 115162.
|
| [86] |
Wang L J, He L, Hao L, et al. Isoliquiritigenin ameliorates caerulein-induced chronic pancreatitis by inhibiting the activation of PSCs and pancreatic infiltration of macrophages[J]. J Cell Mol Med, 2020, 24(17): 9667-9681.
|
| [87] |
Zhang G, Tang L, Liu H, et al. Psidium guajava Flavonoids Prevent NLRP3 Inflammasome Activation and Alleviate the Pancreatic Fibrosis in a Chronic Pancreatitis Mouse Model[J]. Am J Chin Med, 2021, 49(8): 2001-2015.
|
| [88] |
Choi JW, Jeong JH, Jo IJ, et al. Preventive Effects of Gardenia jasminoides on Cerulein-Induced Chronic Pancreatitis[J]. Am J Chin Med, 2020, 48(4): 987-1003.
|
| [89] |
Su SB, Xie MJ, Sawabu N, et al. Suppressive effect of herbal medicine saikokeishito on acinar cell apoptosis in rat spontaneous chronic pancreatitis[J]. Pancreatology, 2007, 7(1): 28-36.
|
| [90] |
Chen YX, Gao QY, Zou TH, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 267-275.
|
| [91] |
Kuratsune H, Umigai N, Takeno R, et al. Effect of crocetin from Gardenia jasminoides Ellis on sleep: a pilot study[J]. Phytomedicine, 2010, 17(11): 840-843.
|
| [92] |
Sharifi N, Amani R. Vitamin D supplementation and non-alcoholic fatty liver disease: A critical and systematic review of clinical trials[J]. Crit Rev Food Sci Nutr, 2019, 59(4): 693-703.
|
| [93] |
Reda D, Elshopakey GE, Albukhari TA, et al. Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway[J]. Front Pharmacol, 2023, 14: 1164512.
|
| [94] |
Klapdor S, Richter E, Klapdor R. Vitamin D status and per-oral vitamin D supplementation in patients suffering from chronic pancreatitis and pancreatic cancer disease[J]. Anticancer Res, 2012, 32(5): 1991-1998.
|
| [95] |
Wallbaum P, Rohde S, Ehlers L, et al. Antifibrogenic effects of vitamin D derivatives on mouse pancreatic stellate cells[J]. World J Gastroenterol, 2018, 24(2): 170-178.
|
| [96] |
Bläuer M, Sand J, Laukkarinen J. Physiological and clinically attainable concentrations of 1, 25-dihydroxyvitamin D3 suppress proliferation and extracellular matrix protein expression in mouse pancreatic stellate cells[J]. Pancreatology, 2015, 15(4): 366-71.
|
| [97] |
Zaafan MA, Abdelhamid AM. Dasatinib ameliorates thioacetamide-induced liver fibrosis: modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/smads pathways[J]. J Enzyme Inhib Med Chem, 2022, 37(1): 118-124.
|
| [98] |
Cruz FF, Horta LF, Maia Lde A, et al. Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis[J]. PLoS One, 2016, 11(1): e0147005.
|
| [99] |
Mukhopadhyay P, Horváth B, Rajesh M, et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis[J]. J Hepatol, 2017, 66(3): 589-600.
|
| [100] |
Zeng XP, Wang LJ, Guo HL, et al. Dasatinib ameliorates chronic pancreatitis induced by caerulein via anti-fibrotic and anti-inflammatory mechanism[J]. Pharmacol Res, 2019, 147: 104357.
|
| [101] |
El-Hamoly T, Hajnády Z, Nagy-Pénzes M, et al. Poly(ADP-Ribose) Polymerase 1 Promotes Inflammation and Fibrosis in a Mouse Model of Chronic Pancreatitis[J]. Int J Mol Sci, 2021, 22(7): 3593.
|
| [102] |
Bansod S, Saifi MA, Godugu C. Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model[J]. Sci Rep, 2021, 11(1): 12894.
|
| [103] |
Nambiar A, Kellogg D, 3rd, Justice J, et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability[J]. EBioMedicine, 2023, 90: 104481.
|
| [104] |
Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate(Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial[J]. Ann Rheum Dis, 2011, 70(6): 1003-1009.
|
| [105] |
Otsuki M, Pathophysiological role of cholecystokinin in humans[J]. J Gastroenterol Hepatol, 2000, 15 Suppl: D71-83.
|
| [106] |
Chandra R, Liddle RA. Cholecystokinin[J]. Curr Opin Endocrinol Diabetes Obes, 2007, 14(1): 63-67.
|
| [107] |
Berna MJ, Seiz O, Nast JF, et al. CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production [J]. J Biol Chem, 2010, 285(50): 38905-38914.
|
| [108] |
Shiratori K, Takeuchi T, Satake K, et al. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan[J]. Pancreas, 2002, 25(1): e1-5.
|
| [109] |
Smith JP, Cooper TK, McGovern CO, et al. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice[J]. Pancreas, 2014, 43(7): 1050-1059.
|
| [110] |
Nadella S, Ciofoaia V, Cao H, et al. Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis[J]. Dig Dis Sci, 2020, 65(5): 1376-1384.
|